AVEO Pharmaceuticals (AVEO) Receiving Somewhat Positive Media Coverage, Study Finds

Media headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.6717129433843 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

AVEO Pharmaceuticals traded up $0.10, reaching $2.40, during midday trading on Friday, according to MarketBeat. 203,511 shares of the company’s stock were exchanged, compared to its average volume of 1,247,548. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of -0.36. The stock has a market cap of $284.09 million, a P/E ratio of -15.00 and a beta of 1.52. AVEO Pharmaceuticals has a 1-year low of $0.68 and a 1-year high of $4.24.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.98 million. analysts forecast that AVEO Pharmaceuticals will post -0.27 EPS for the current fiscal year.

AVEO has been the subject of several recent analyst reports. BidaskClub cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 27th. ValuEngine upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, May 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.05.

In other AVEO Pharmaceuticals news, major shareholder Ravi Viswanathan bought 70,873 shares of the business’s stock in a transaction on Tuesday, May 8th. The stock was bought at an average price of $2.13 per share, for a total transaction of $150,959.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Equity Opportunities Iv Growth bought 236,479 shares of the business’s stock in a transaction on Monday, May 21st. The shares were acquired at an average price of $2.13 per share, with a total value of $503,700.27. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 2,098,458 shares of company stock valued at $4,701,711. 4.40% of the stock is currently owned by company insiders.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply